Release Date: December 23, 2025
Expiration Date: December 23, 2026
Activity Overview
This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of platinum-resistant ovarian cancer, with a forward-looking perspective on how new and novel agents might impact clinical practice. Mechanisms of action and clinical trial data for novel antibody-drug conjugates, glucocorticoid receptor inhibitors, and oncolytic viruses will be presented in a multimedia format, including a series of video interviews with an expert thought leader integrated into text-based elements.
Target Audience
This educational activity is directed toward community and academic-based medical oncologists, gynecologic oncologists, NPs/PAs, nurses, pharmacists, and other health care providers interested in the treatment of ovarian cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Incorporate the latest evidence and guideline recommendations on currently available agents into personalized treatment strategies for patients with platinum-resistant ovarian cancer (PROC)
- Describe key features and novel mechanisms of emerging therapies under investigation for the treatment of PROC
- Evaluate the efficacy and safety of emerging therapies for PROC, including antibody-drug conjugates, glucocorticoid receptor modulators, and novel immunotherapies
Alexander Olawaiye, MD
Professor of Obstetrics, Gynecology and Reproductive Sciences
and Professor of Gynecologic Oncology
Vice Chair of DEI, Department of Obstetrics, Gynecology and
Reproductive Sciences
University of Pittsburgh
Pittsburgh, PA
Disclosures: Adviser, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Corcept, Daiichi Sankyo, Eisai, Eli Lilly, GSK, Merck; Grant/Research Funding: AstraZeneca, Corcept
Alison Schram, MD
Associate Attending Physician
Early Drug Development and Gynecologic Medical Oncology
Services
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Adviser, Consultant, Speaker, Honoraria Recipient: Boehringer Ingelheim, Guardant, Merus, Partner Therapeutics, Revolution Medicines. Grant/Research Funding: AstraZeneca, BeiGene, Boehringer Ingelheim, Kura, Lilly, Merus, Partner Therapeutics, Pfizer, Relay, Revolution Medicines
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.